Female, n (%) |
19 (90.5%) |
12 (75.0%) |
2.11 (0.40 to 11.13) |
0.64 |
Age, mean (SD), year |
|
|
|
|
At onset |
9.8 (3.7) |
9.4 (3.2) |
-0.45 (-2.81 to 1.90) |
0.70 |
At HCQ initiation |
12.3 (2.6) |
11.5 (2.4) |
-0.74 (-2.46 to 0.98) |
0.39 |
Interval from ITP onset to HCQ initiation, mean (SD), months |
28.9
(28.9) |
25.4 (18.2) |
-3.48 (-20.26 to 13.29) |
0.68 |
Platelet counts at onset, mean (SD), 109/L |
25.6
(18.7) |
23.5 (24.2) |
-2.07 (-18.23 to 14.10) |
0.80 |
Symptoms associated with autoimmune diseases *, n (%) |
12 (57.1%) |
8 (50.0%) |
1.33 (0.36 to 4.93) |
0.67 |
Positive ANA at baseline, n (%) |
10 (47.6%) |
8 (50.0%) |
0.91 (0.25
to 3.34) |
0.89 |
Other markers associated with autoimmune diseases, n (%) |
14 (66.7%) |
11 (68.8%) |
0.91 (0.23 to 3.67) |
0.89 |
Positive antiphospholipid antibodies †
|
10 (47.6%) |
9 (56.3%) |
0.71 (0.19 to 2.61) |
0.60 |
Low C3/C4 |
9 (42.9%) |
4/14 (28.6%) |
1.88 (0.44 to 7.96) |
0.49 |
Response to HCQ at 1 year from initiation, n (%) |
|
|
|
|
R |
2 (9.5%) |
- |
- |
- |
CR |
13 (61.9%) |
- |
- |
- |
Loss of CR/R |
2 (9.5%) |
- |
- |
- |
NA |
4 (19.0%) |
- |
- |
- |
Combined therapy |
|
|
|
|
Monotherapy |
4 (19.0%) |
10 (62.5%) |
0.14 (0.03 to 0.62) |
0.007 |
Corticosteroids |
14 (66.7%) |
4 (25.0%) |
6.00 (1.41 to 25.59) |
0.01 |
TPO-RAs |
3 (14.3%) |
2 (12.5%) |
1.17 (0.17 to 7.96) |
>
0.999 |
Autoimmune diseases progression ‡, n (%) |
4 (19.0%) |
3 (18.8%) |
1.02 (0.19 to 5.37) |
> 0.999 |